{"commentary":{"count":77,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":48,"podcast":27,"x_thread":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01969838\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"Simplify 1","nct_id":"NCT01969838","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=simplify-1-nct01969838. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"Simplify 1","arms":[{"description":"Participants will receive momelotinib plus placebo to match ruxolitinib.","label":"Momelotinib","type":"EXPERIMENTAL"},{"description":"Participants will receive ruxolitinib plus placebo to match momelotinib.","label":"Ruxolitinib","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2019-05-02","type":"ACTUAL"},"conditions":["Primary Myelofibrosis","Post-Polycythemia Vera Myelofibrosis","Post-Essential Thrombocythemia Myelofibrosis"],"enrollment":{"count":432,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Momelotinib","type":"DRUG"},{"name":"Ruxolitinib","type":"DRUG"},{"name":"Placebo to match momelotinib","type":"DRUG"},{"name":"Placebo to match ruxolitinib","type":"DRUG"}],"last_update":"2023-05-12","lead_sponsor":"Sierra Oncology LLC - a GSK company","official_title":"A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2016-09-12","type":"ACTUAL"},"primary_outcomes":[{"measure":"Splenic Response Rate at Week 24","timeFrame":"Week 24"}],"references":[{"citation":"Palandri F, O'Connell C, Vachhani P, McLornan DP, Koschmieder S, Hernandez-Boluda JC, Shimoda K, Zhang S, Ellis C, Lim J, Sahni J, Gupta V. Impact of Hemoglobin Improvement on Survival in Patients With Myelofibrosis and Anemia Treated With Momelotinib in the SIMPLIFY-1 and MOMENTUM Trials. Eur J Haematol. 2026 Jul 14. doi: 10.1111/ejh.70237. Online ahead of print.","pmid":"42452788","type":"DERIVED"},{"citation":"Pemmaraju N, Lucchesi A, Oh ST, Wilson K, Hakimi Z, Buckley SA, Suthar P, Parkitny M, Wojciechowski P, Kolonko K, Mascarenhas JO. Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison. Expert Rev Hematol. 2026 Sep;19(9):1107-1115. doi: 10.1080/17474086.2026.2686813. Epub 2026 Jun 30.","pmid":"42316774","type":"DERIVED"},{"citation":"Mesa R, Palmer JM, Palandri F, Masarova L, Harrison CN, Mazerolle F, M'hari M, Liu T, Zhang S, Cardellino A, Wang Z, Ellis CE, Patnaik D, Regnault A, LeBlanc TW. Association Between Transfusion Status, Hemoglobin Levels, and Patient-Reported Outcomes in Myelofibrosis: A Post Hoc Clinical Trial Analysis. Cancer Med. 2026 Apr;15(4):e71729. doi: 10.1002/cam4.71729.","pmid":"41958363","type":"DERIVED"},{"citation":"Mesa RA, Talpaz M, Mazerolle F, Gorsh B, M'Hari M, Regnault A, Ellis C, Wang Z, Purser M, Liu T, Strouse B, Patnaik D. Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM Trials. EJHaem. 2025 Jun 18;6(3):e70075. doi: 10.1002/jha2.70075. eCollection 2025 Jun.","pmid":"40535755","type":"DERIVED"},{"citation":"Harrison CN, Mesa R, Talpaz M, Gupta V, Gerds AT, Perkins A, Goh YT, Fox ML, McLornan D, Palmer J, Foltz L, Vannucchi A, Koschmieder S, Passamonti F, Lee SE, Ellis C, Strouse B, Gonzalez Carreras FJ, Oh ST. Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib. Clin Lymphoma Myeloma Leuk. 2025 Mar;25(3):199-211. doi: 10.1016/j.clml.2024.10.001. Epub 2024 Oct 16.","pmid":"39516087","type":"DERIVED"},{"citation":"Gupta V, Oh S, Devos T, Dubruille V, Catalano J, Somervaille TCP, Platzbecker U, Giraldo P, Kosugi H, Sacha T, Mayer J, Illes A, Ellis C, Wang Z, Gonzalez Carreras FJ, Strouse B, Mesa R. Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial. Leuk Lymphoma. 2024 Jul;65(7):965-977. doi: 10.1080/10428194.2024.2328800. Epub 2024 Mar 19.","pmid":"38501751","type":"DERIVED"},{"citation":"Verstovsek S, Mesa R, Gupta V, Lavie D, Dubruille V, Cambier N, Platzbecker U, Hus M, Xicoy B, Oh ST, Kiladjian JJ, Vannucchi AM, Gerds A, Egyed M, Mayer J, Sacha T, Kawashima J, Morris M, Huang M, Harrison C. Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials. Blood Adv. 2023 Jul 25;7(14):3582-3591. doi: 10.1182/bloodadvances.2022009311.","pmid":"37042865","type":"DERIVED"}],"start_date":{"date":"2013-12-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis","url":"https://clinicaltrials.gov/study/NCT01969838"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/simplify-1-nct01969838"}